Shares of Vivus (VVUS) continue their restless ways, up 6.3% premarket, after analysts continue...

|By:, SA News Editor

Shares of Vivus (VVUS) continue their restless ways, up 6.3% premarket, after analysts continue to tag the company as an acquisition target following the firm's well-publicized FDA panel recommendation for its weight-loss drug.